Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation : A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes
OBJECTIVE: Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS: A phase 3, multicenter, randomized, double-blind, parallel-assignment study (NCT01817959) was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition
